Predicting the Response to Montelukast by Genetic Variation in Asthmatics

Completed · Phase 3

Conditions studied: Asthma

In brief

The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast than patients with the wild type gene, as measured by the ability of montelukast to protect against a hypertonic saline challenge.

Key facts

Study ID
NCT00116324
Run by
Brigham and Women's Hospital
People needed
150
Starts
2003-04-01
Expected to finish
2006-12-01
Last updated by the study team
2021-05-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.